A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer.

To determine the maximum-tolerated doses (MTDs), the dose-limiting toxicities (DLTs) and the recommended doses for further trials of docetaxel in combination with a 5-day continuous infusion of 5-fluorouracil (5-FU) in advanced or recurrent breast cancer patients who had been treated previously with...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ando, M., Watanabe, T., Sasaki, Y., Ying, D. F., Omuro, Y., Katsumata, N., Narabayashi, M., Tokue, Y., Fujii, H., Igarashi, T., Wakita, H., Ohtsu, T., Itoh, K., Adachi, I., Taguchi, T.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 1998
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2150334/
https://ncbi.nlm.nih.gov/pubmed/9667671
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars